Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407441 | 0.91 | KDM4E (0.52) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL9547380 | 0.83 | KDM4E (0.44) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL12265757 | 0.83 | KDM4E (0.44) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL18506889 | 0.83 | PAOX (0.45) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL8927622 | 0.81 | PAOX (0.50) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL15146684 | 0.80 | KDM4E (0.46) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL25817395 | 0.79 | KDM4E (0.58) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL23794346 | 0.78 | KDM4E (0.40) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL15473842 | 0.78 | ALDH1A1 (0.43) | KDM4EMAPK1HIF1AMTNR1AMTNR1B | |
| SCHEMBL13135939 | 0.78 | MTNR1A (0.41) | KDM4EMAPK1HIF1AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| EP-2975030-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | SLC9A5, SLC5A2, SLC5A1 | KDM4E 2054/4885MAPK1 1890/4885HIF1A 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.